2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Sales - EUR | - | - | - | - | - | 1.201 | 13.510 | 40.659 | 217.032 | 481.124 |
Total Income - EUR | - | - | - | - | - | 1.201 | 13.510 | 40.659 | 221.348 | 493.981 |
Total Expenses - EUR | - | - | - | - | - | 2.023 | 10.510 | 27.615 | 189.860 | 388.928 |
Gross Profit/Loss - EUR | - | - | - | - | - | -822 | 3.000 | 13.044 | 31.489 | 105.052 |
Net Profit/Loss - EUR | - | - | - | - | - | -858 | 2.615 | 11.825 | 28.926 | 101.045 |
Employees | - | - | - | - | - | 0 | 1 | 1 | 5 | 6 |
Check the financial reports for the company - Elixir & Anaid Beauty Med S.r.l.
See the company's note based on the submitted financial data, relative to the industry of which it is a part.
Check Financial Rating2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Fixed Assets | 198.040 | 154.633 | 2.872 | 3.390 | 3.964 | - | - | - | - | - |
Current Assets | - | - | - | - | - | 720 | 532 | 13.396 | 24.970 | 10.260 |
Inventories | - | - | - | - | - | 322 | 447 | 283 | 0 | 0 |
Receivables | - | - | - | - | - | 0 | 0 | 12.832 | 24.037 | 3.599 |
Cash | - | - | - | - | - | 398 | 85 | 280 | 933 | 6.660 |
Shareholders Funds | - | - | - | - | - | -816 | 1.814 | 13.599 | 28.974 | 106.863 |
Social Capital | - | - | - | - | - | 42 | 41 | 40 | 41 | 40 |
Debts | - | - | - | - | - | 5.500 | 2.108 | 2.668 | 150.629 | 101.436 |
Income in Advance | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
Exchange rate - RON | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 | 4.4821 |
Main CAEN | "8622 - 8622" | |||||||||
CAEN Financial Year | 8622 |
Subscriptions Financial Reports
You can check the financial situation of the companies in relation to the industry of which it is a part, credit limits and the risk of insolvency and suspension of accounts.
Reports that can be accessed based on the subscription:
Get the contact details for any company and get in touch with it.